arrow
M

Míriam Rosás-Umbert

Aarhus University
H指数:14
被引数:889

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunological Dysfunction Associated with SARS-CoV-2 Persistence in Immunocompromised Patients

与免疫缺陷患者中SARS-CoV-2持续性相关的免疫功能障碍

2026-04-080
PRE
Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control

自体中和抗体和多功能T细胞有助于长期HIV-1干预后控制

2026-03-030
OA
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

TLR9激动剂和广泛中和抗体对HIV-1持久性的影响: TITAN 2a期随机试验

2023-09-1123
OAAI
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity

在ART起始时给予广泛中和性anti-HIV-1抗体维持长期CD8 T细胞免疫

2022-10-2933
OAAI
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial

HTI疫苗在早期治疗的HIV-1感染中的安全性,免疫原性和对病毒反弹的影响: 一项随机,安慰剂对照的1期试验

2022-10-2733
OA
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

3BNC117和romidepsin在HIV-1患者抗逆转录病毒治疗开始时的早期干预: 1b/2a期随机试验

2022-10-1752
OA
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome

kick-and-kill治疗性疫苗BCN02临床试验中的表观遗传景观与抗逆转录病毒治疗中断 (ATI) 结果相关

2022-04-016
OAAI
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)

HIVconsv疫苗和Romidepsin在早期治疗的HIV-1-Infected个体: 安全性,免疫原性和对病毒库的影响 (研究BCN02)

2020-05-0664
OAAI
Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study) (vol 11, pg 65, 2019)
2020-01-010
OAAI
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
2019-05-0151
OAAI
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1

改良的安卡拉痘苗HIV-1疫苗 (mva-b) 在HIV-1-infected患者中单独或与药物联合使用以重新激活潜伏HIV-1的安全性和免疫原性

2015-02-2656
OAAI